Investor Presentation for FY 2025.
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals has filed its FY25 Investor Presentation with BSE, highlighting its position as a manufacturer of complex injectables in India. Revenue grew from INR 251 Cr in FY23 to INR 370 Cr in FY25, a 3-year CAGR of 21.4%, while profit after tax jumped to INR 40 Cr in FY25 from INR 19 Cr in FY23. The company operates 5 manufacturing facilities across Amritsar and Jassur, employs 700+ people including 80+ in R&D, and exports to 40+ markets with regulatory accreditations from agencies such as EU GMP, SFDA, ANVISA, and WHO GMP. It has a strong complex injectables pipeline (Liposomal, Pegylated, Microspheres, Peptide-based) with 10+ products filed and 7+ approved, plus a biologics pipeline (Erythropoietin, Etanercept, Peg Asparaginase) targeted for FY26–FY27 launches. Management has set a consolidated revenue target of INR 500 Cr for FY26 (dubbed the 'Year of Focus') and guided EBITDA margins in the 22-25% range.
Positive for shareholders — strong revenue growth, rising profits, clear FY26 revenue and margin guidance, and a visible pipeline of complex injectables and biologics suggest continued momentum. Investors should watch for execution of the INR 500 Cr target and timely biologics approvals as key catalysts.